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Abstract
Background: Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis, with ~50,000 cases
reported annually worldwide. Vaccination is the only measure for prevention. Recombinant vaccines are an efficient
and safe alternative for formalin inactivated or live attenuated vaccines. Nowadays, incorporation of molecular
adjuvants has been the main strategy for melioration of vaccines. Our attempt of immunomodulation is based on
targeting antigen presenting cells (APC) “majorly macrophages” by using macrosialin promoter. We have compared
the immune response of the constructed plasmids expressing JEV envelope (E) protein under the control of
aforesaid promoter and cytomegalovirus (CMV) immediate early promoter in mouse model. Protection of
immunized mice from lethal challenge with JEV was also studied.
Results: The E protein was successfully expressed in the macrophage cell line and was detected using
immunofluorescence assay (IFA) and Western blotting. APC expressing promoter showed comparable expression to
CMV promoter. Immunization of mice with either of the plasmids exhibited induction of variable JEV neutralizing
antibody titres and provided protection from challenge with a lethal dose of JEV. Immune splenocytes showed
proliferative response after stimulation with the JEV antigen (Ag), however, it was higher for CMV promoter. The
magnitude of immunity provided by APC dominant promoter was non-significantly lower in comparison to CMV
promoter. More importantly, immune response directed by APC promoter was skewed towards Th1 type in
comparison to CMV promoter, this was evaluated by cytokine secretion profile of immune splenocytes stimulated
with JEV Ag.
Conclusions: Thus, our APC-expressing DNA vaccination approach induces comparable immunity in comparison to
ubiquitous promoter construct. The predominant Th1 type immune responses provide opportunities to further test
its potency suitable for response in antiviral or anticancer vaccines.
Background
JEV belongs to the family Flaviviridae.I ti st r a n s m i t t e d
to humans by mosquitoes leading to the infection of cen-
tral nervous system and encephalitis. JEV has covered a
vast geographic area of Asia and parts of Oceania [1].
Nearly half of the human population falls in countries
where JEV occurs, globally 50,000 cases are reported with
15,000 mortality rate per year [2-5].
Vaccination is the only way in controlling JEV out-
breaks. Several such vaccines have been used with con-
siderable success. The only WHO recommended vaccine
used worldwide was BIKEN which was a formalin inacti-
vated vaccine from infected mouse brain. Live-attenuated
JE vaccine (SA 14-14-2) prepared in infected primary
hamster kidney cells is used in China for many years and
is in use by other countries like India and Nepal in recent
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has also been licensed. Chimeric Yellow fever-JE vaccine
is undergoing phase III trial [6]. Each of these vaccines
have their own drawbacks [7,8], and as such there is a
need for the development of safer and cost effective
vaccine with higher potency which can elicit both the
arms of immune response, such as DNA vaccines [9].
JEV is a single stranded, positive sense RNA virus.
The genomic RNA is ~11 kb with single open reading
frame (ORF) that encodes structural protein (capsid (C),
premembrane (prM) and E) followed by seven non-
structural protein (NS1 to NS5) [10,11]. E protein plays
a major role in the infection, such as receptor binding
and membrane fusion [12]. E protein induces virus neu-
tralizing antibodies and these have been shown to neu-
tralize virus activity through passive administration in
mice model also [13]. For proper folding of E protein,
co-synthesis of prM protein is required [14]. Subvirus
particle with only prM and E protein has also generated
protection against lethal JEV infection [15]. DNA vac-
cine encoding E protein is considered to be highly effec-
tive in providing protective immunity when compared
with other proteins of JEV [16].
With the growing knowledge of molecular information
on JEV, recombinant vaccines using various approaches
[17] with different gene products [18-20] have been tried.
Such vaccines have shown considerable success albeit with
some shortcomings; either in terms of evoking suboptimal
response or not maintaining the balance between Th1 and
Th2 response [21]. Therefore the present attention has
shifted towards the improvement of DNA vaccine modu-
lated through several immunological adjuvants, such as
the use of liposomes [22], inclusion of CpG motif [23], co-
expressing cytokines and costimulatory molecules along
with the target gene [24], exploring different routes of
administration of vaccine [25-27], targeting the vaccine to
specific cells [28] or endosomal/lysosomal compartment
[29].
One such optimization is to target the antigen expres-
sion in professional APC by using promoters active only
in APC [30]. Dendritic cell (DC) as an APC have prefer-
ence over macrophage and B cells as a potent cell in prim-
ing and stimulating naïve T cells. Langerhans cells have
been targeted using Dectin-2 promoter [31]. For the treat-
ment of HIV-1, APC have been targeted [32]. Lentiviral
vectors were used to deliver the gene into APC [33].
Immune response to any antigen is a highly intricate
and balanced mechanism. To prevent unwanted immune
responses like autoimmunity, hypersensitivity and to
induce long term antigen specific immunity, specific cells
with appropriate cytokine and cell surface antigen milieu
have been devised by immune system. Presentation of
antigen through APC would thus be the most desirable
approach while developing newer vaccine. Although, DC
specific promoter has shown promising results, meagrely
targeting DC was reported to be insufficient to optimally
induce T cell immunity [34,35]. Therefore the role of
other professional APC (Macrophage and B-cells) needs
to be considered. Studies suggest macrophages are potent
enough to stimulate naïve CD8+ T cells to proliferate
and mature [36] and could be as good as DC in cross
presentation of antigen [37]. Thus there is a need to
explore promoters which could be active also in other
cells of APC and just not a single population.
Our earlier work for initial screening of promoters
was carried out in macrophage and non-macrophage
cell lines at the level of mRNA and protein using GFP
as a reporter system [38]. Briefly, three promoters were
selected based on their known expression profiles.
Macrosialin, is a glycoprotein expressed specifically in
murine monocytes and macrophages and to a lesser
extent by DC [39-41]. Activity of this promoter along
with two other promoters; Emr-1 [42-44] and Beta-5
Integrin [45,46], was compared with immediate early
promoter of CMV. Macrosialin was chosen for further
studies as it showed the highest expression amongst the
APC expressing promoters albeit to a lesser extent in
comparison to CMV promoter.
To study the effect of APC dominant expression as
against ubiquitous expression on protective immune
response, JEV system has been used. We report here
studies carried out by immunizing mice with plasmids
expressing JEV E protein under macrosialin promoter
and comparing it with CMV promoter in terms of pro-
tective immunity and immune balance.
Methods
Virus and Antigen
JEV strain 733913 was used in all experiments [47].
Virus pools were prepared for ex vivo experiments in
porcine stable kidney (PS) cells. For in vivo experiment
two days old infant mouse brain derived virus pool sus-
pended in 0.75% bovine serum albumin (BSA) in PBS
w a su s e d .V i r u ss t o c k sw e r es t o r e da t- 7 0i na l i q u o t s
and titrated using plaque assay and in two months old
mice group respectively. Mouse brain antigen (MbrAg)
for mice inoculation was prepared in borate saline con-
taining 8.5% sucrose, homogenized and inactivated with
b-propiolactone. For ex vivo studies, cell culture derived
virus antigen as cell slurry was used [48].
Cell Culture
PS cells (National Center for Cell Sciences (NCCS),
Pune, India) were maintained in minimal essential med-
ium (MEM) (Sigma) supplemented with 2 mmol/l L-glu-
tamine and 10% fetal bovine serum (FBS) (Gibco, USA).
Whereas RAW264.7 cells (NCCS, Pune, India) were
maintained in high glucose DMEM with 10% FBS
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and streptomycin (100 μg / m l )a t3 7 ° Cw i t h5 %C O 2i n
humidified environment. For all transfections studies,
cells were maintained without antibiotics.
Mice
Mice (BALB/c) of different age group i.e. infants, 2 months
old and 4-5 week old females were procured from the ani-
mal house facility of National Institute of Virology, Pune,
India. All animals were maintained according to the guide-
lines of Committee of Protection, Supervision and Control
of Experiments on Animals. The project was approved by
Indian GMO Research Information System (IGMORIS)
and Institutional Biosafety Committee (IBSC).
Cloning
Plasmid used in the study was pAcGFP1-N1 (Clonetech,
Takara). For the construction of (pCMV-E) construct, JEV
propagated from tissue culture fluid of PS cells was used
for RNA isolation (Trizol reagent, Invitrogen). The frag-
ment of 2047 bp of partial C, prM and E gene [GenBank:
EU372660] was amplified with Forward primer: 5’-
GGTACCATGTGGCTCGAGAGCTTG-3’ and Reverse
primer: 5’-GGATCCTTTATTAAGCATGGACATTGG
TCGCTA-3’ employing Reverse Transcriptase PCR, using
MMLV-RT and Platinum Taq. Start and stop codon
(underlined) were included in forward and reverse primer
respectively. Amplicon after cloning in pGEM
®-T Easy
cloning vector (Promega Corporation, Madison, USA) was
excised using EcoRI restriction enzyme and cloned in
EcoRI digested pAcGFP1-N1 expression vector. For
(pMS-E), macrosialin promoter [GenBank: AF039399],
was amplified with Forward primer: 5’-TATTAATGAC-
CAAATCTACAGGGAGAACCC-3’ and Reverse primer:
5’-AGCGCTAGATGCTCAGACCAGCTA-3’ with VspI/
Eco47III incorporated (underlined) and cloned in Strata-
Clone™ PCR Cloning kit (Stratagene, USA). After diges-
tion with VspI/Eco47III it was subcloned in similar
digested pCMV-E construct and ligated. Devoid of promo-
ter a negative control vector (pNIX-E) was constructed as
described elsewhere [38]. Orientation and codon in-frame
for all reconstructed clones were confirmed through
restriction analysis (Figure 1) and sequencing.
Purified plasmids were prepared using EndoFree
®
Plasmid Maxi Kit (Qiagen, Germany), according to man-
ufacturer’s instruction. The quality of plasmid was
assessed using Nanodrop by light absorption at 260/280
nm ratio and by 1% agarose gel electrophoresis. All the
plasmids were dissolved in sterile PBS for in vivo studies
and nuclease free water for ex vivo studies.
Western blot
Transfection was carried out with different constructs
encoding E protein of JEV using Lipofectamine™2000
(Invitrogen, USA) with 2 μg of DNA as per manufacturer’s
instruction. Analysis for the blot was performed with
50 μg of cell lysate from RAW 264.7 cells. After 24 hours
of transfection, cells were harvested, washed, mixed with
an equal volume of 2× loading buffer and boiled for
10 min. Proteins were separated onto a discontinuous
SDS-polyacrylamide gel with 5% stacking gel and 10%
resolving gel and transferred to a nitrocellulose membrane
(Amersham Biosciences, USA). The membrane was
blocked by 5% skimmed milk powder in PBS and incu-
bated with anti JEV monoclonal antibody [47] followed by
goat anti-mouse IgG-HRP conjugate (Sigma). Bands were
developed with diaminobenzidine tetrahydrochloride-
H2O2 solution.
Immunofluorescence assay
RAW264.7 cells grown on coverslips were transfected
with pCMV-E, pMS-E and pNIX-E for 24 hours. The
cells were fixed with 4% paraformaldehyde for 10 min
and blocked with 1% BSA in PBS. The cells were per-
meabilized for detection of E protein, anti JEV monoclo-
n a la n t i b o d i e sw e r eu s e da sp r i m a r ya n t i b o d ya n d
probed with goat anti-mouse IgG FITC-conjugated Ab
(Sigma, USA). The fluorescence was observed under
confocal microscope.
Mouse immunization and challenge experiments
Immunization studies were carried out in female inbred
BALB/c mice aged between 4-5 weeks. Animals were
divided into groups of 14, each for the following constructs:
pCMV-E, pMS-E, pNIX-E, pCMV-E/MbrAg and PBS. All
constructs were suspended in PBS with concentration of 1
μg/μla n da n t i g e nw i t h0 . 5μg/μl with 100 μl inoculated.
Mice were anesthesised and injected through i.m. route
with 50 μl of constructs in both left and right quadriceps
muscle. Animals in each group were given booster injec-
tion with the same concentration after 3 weeks of primary
immunization and the next booster after 2 weeks. In
pCMV-E/JE-MbrAg group, DNA construct followed by
MbrAg as boosters were inoculated. After 7 weeks of
immunization, all mice were challenged with lethal dose of
JEV strain 733913 (100 LD50) through i.p. route followed
by 1% starch by the i.c. route in order to breach the blood
brain barrier [49]. These mice were observed for mortality
for 6 weeks after challenge. Sera samples were collected by
capillary through orbital sinus bleeding method at different
time points and antibody response were assessed. To deter-
mine the 50% lethal dose (LD50) beforehand, groups of
11-12 weeks old mice were injected with i.p./i.c. starch
route with 10 fold serial dilutions of virus.
Enzyme Linked Immunosorbent Assay (ELISA)
Standard protocols for ELISA were used. Briefly, tissue
culture derived JEV Ag (1 μg) was coated overnight in
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PBS, 100 μl of diluted mouse serum was added per well
and incubated for 1 hr. After washing with PBST (PBS
with 0.1% Tween 20), 100 μlo fg o a ta n t i - m o u s eI g G -
HRP conjugate (1:5000, Sigma) was added in each well.
The colour was developed using the substrate orthophe-
nyl-diamine (OPD) solution. The reaction was stopped
with 100 μlo f4NH 2SO4. The absorbance was mea-
sured at 490 nm on a microplate reader (680 XR Micro-
plate Reader). The end point titres of antibodies were
determined as the reciprocal of highest dilution that
gave an absorbance two times higher than that of non-
immune serum.
Neutralization Assay
The virus neutralization assay was performed to assess the
ability of produced antibody to neutralize the live JEV. As
a positive serum JEV immune peritoneal fluid was used.
The test was carried out with pooled mice sera of each
group (pCMV-E, pMS-E, pNIX-E, pCMV-E/MbrAg and
PBS) collected at day 0, 21, 36 and 51 before booster
immunizations and complement inactivated. PS cells were
seeded in 96 well plate with a density of 2 × 10
5 cells/ml
in MEM supplemented with 10% FBS and incubated over-
night. Fivefold serial dilution (1:10 to 1:1250) of serum
along with controls was carried out in round bottomed
microtitre plate (Nunc) and mixed with equal volume
(60 μl) of 100 TCID50 of tissue culture pool of virus in
MEM with 5% FCS. After incubation at 37°C for 1 hr,
100 μl of this antibody virus mixture was added to the pre-
formed monolayer of cells and incubated for 3 days. Virus
titration for determining the dose was challenge virus,
incorporated in each plate. NT titre was expressed as reci-
procal of serum dilution that resulted in more than 50%
CPE [50].
Cytokine profiling
Three weeks after the last immunization, splenocytes
were harvested and resuspended at 2 × 10
5 cells/ml in
RPMI 1640 (Gibco, USA) supplemented with 10% FBS
(Gibco, USA) penicillin (100 IU/ml) and streptomycin
(100 μg/ml). Each well of 24 well plate contained 4 ×
10
5 cells in triplicate for each group. JE antigen (10 μg)
was added to each well. As a positive control Con A
(Sigma, USA) was used. After 72 hours of incubation at
37°C in 5% CO2 the supernatant was collected and cen-
trifuged to remove the cell debris. That supernatant was
stored in -70°C till tested.
The evaluation of Th1 and Th2 cytokine was per-
formed by Cytometric Bead Array (CBA) (BD Bios-
ciences) as per manufacturer’s instruction. Briefly 50 μl
of bead was mixed with the supernatant along with the
given standards and incubated for 2 hours at RT in
dark. The beads were washed and resuspended in 300 μl
of wash buffer. The BD FACSAria™II instrument was
then setup using BD FACSComp software and setup
beads. Following acquisition the cytokine concentration
was determined using the standard curve prepared.
Lymphocyte proliferation assay
The assay was performed using tritiated thymidine incor-
poration as previously described [48]. Splenocytes were
harvested from all the groups and resuspended at 2 × 10
5
cells/well in 96 well flat bottomed plate (Nunc). Cells were
grown in RPMI 1640 (Gibco, USA) supplemented with
10% FBS with antibiotics and pulsed overnight with JEV
antigen. Con A (Sigma, USA) was used as positive control.
The assay was done in triplicates using three different con-
centrations. After 3 days the cells were pulsed with 1 μCi
[
3H] thymidine (BRIT) for 18 h. Cells were harvested onto
GF/C (Whatman) filter disc and thymidine incorporation
was measured with beta liquid scintillation counter (Tri-
Carb
®, PerkinElmer), as cpm. Data were represented as
proliferation indices, calculated as: (Thymidine incorpo-
rated by cells in the presence of E protein/Thymidine
incorporated in the absence of E protein)
Statistical analysis
All of the test data were analyzed with PASW Statistics
(version 18.0). Data were considered to be statistically
significant when P < 0.05
Results
Western Blot Analysis
After 24 hours of transfection similar amount of cell
lysate were subjected to SDS-PAGE (Figure 2A) and
      M            1  M         2       M           3 
5000bp
1650bp
Figure 1 Restriction analysis of the constructs. Independent run gel documented in 1% Agarose in TAE buffer. M: 1 Kb+ Ladder (Invitrogen);
1: pCMV-E with SacI digested (Fragments: 4999 & 1812 bp); 2: pMS-E with VspI + NotI digested (Fragments: 2926 + 1551 + 703 bp); 3: pNIX-E
(Undigested).
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antibody against E protein reacted specifically with E
protein of ~54 and prM of 20 kDa (Figure 2B, 1, 2). No
visible band was observed in the lane of non transfected
cells (Figure 2B, 3) indicative of absence of E and prM
protein in the sample.
Immunofluorescence assay
After the transfection, immunofluorescence analysis
showed the green fluorescent cells which represented
the expression of E gene of JEV (Figure 3A-B). No such
signal was detected in the cells transfected with pNIX-E
or untransfectd cells (Figure 3C-D).
Mouse challenge experiments
Post immunization, no visible side effects were observed
in the mice due to any of the construct used. To study
the potency of vaccine, the immunized mice were chal-
lenged with lethal dose (100LD50) of JEV by previously
reported method [48]. As JEV is not pathogenic by intra
peritoneal (i.p.) route, following virus administration by
i.p. route, blood brain barrier is breached by administra-
tion of 1% starch by intra cranial (i.c.) route. The mice
were observed for mortality for 6 weeks post challenge.
Table 1 depicts that the mice immunized with pCMV-
Es h o w s8 7 . 5 %p r o t e c t i o na g a inst lethal challenge of
JEV. The newly constructed vaccine pMS-E was effective
enough to give 75% protection. None of the mice
survived after challenge from the negative control group
pNIX-E and PBS. Significant level of difference was
observed in groups of pCMV-E, pMS-E and pCMV-E/
MbrAg in comparison to pNIX-E or PBS groups.
ELISA
Antibody response was observed after immunization
with different constructs through ELISA. Serum samples
were collected from mice before every immunization
and two weeks after the last immunization. Pooled sera
were analyzed for the entire group in triplicate. The
highest Ab titre was observed for the pCMV-E/MbrAg
group, followed by pCMV-E and pMS-E, whereas only
basal level of titre was obtained in pNIX-E and PBS
inoculated mice. There were no significant differences
(p > 0.05) in the Ab titre of all the groups in day zero
and after the first dose, however significant increase in
Ab titre after the second dose was observed in (pCMV-
E, pMS-E and pCMV-E/MbrAg) groups which further
increased after the next booster (Figure 4).
Virus neutralization assay
The virus neutralization test was performed to evaluate
the ability of the constructs to elicit a neutralizing Ab
response. Serum from the vaccinated groups showed
considerable titres of JEV neutralizing Ab. Virus neutra-
lizing Ab titres was observed to be 1:500 for the pCMV-
E/MbrAg group, whereas for pCMV-E group it was
    
 M 1  2            3 M            1             2       3
28kDa
55kDa
A B
Figure 2 Western Blot Analysis. (A) 10% SDS-PAGE gel (B) Western blot analysis of the total cell lysates of the RAW 264.7 cells. M: PageRuler™
(Fermentas); 1: pCMV-E; 2: pMS-E; 3: pNIX-E. The blot shows expressed prM and E protein from different constructs after 24 hours of transfection.
        A              B            C                      D
pCMV-E pMS-E pNIX-E Untransfected
Figure 3 Detection of E protein using IFA. Expression of E protein in transfected RAW264.7 cells were detected 24 hrs post transfection.
Figures (A) pCMV-E and (B) pMS-E confirms the expression of E protein whereas Fig. (C) pNIX-E and (D) Untransfected were used as a negative
control.
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titre at 1:300 (Figure 5). This difference was consistent
for the group and reproducible. No such neutralization
Ab activity was observed for pNIX-E and PBS inocu-
lated group.
Cytokine profiling
To characterize the immune response in different vacci-
nated groups, splenocytes were isolated after immuniza-
tion protocol and the responses of T-cells were evaluated
using mouse Th1/Th2 CBA system. This allowed simulta-
neous measurement of Th1 (IL-2, IFN-g and TNF-a) and
Th2 cytokines (IL-4 and IL-5) in antigen stimulated T-
cells supernatant. After immunization in APC promoter
group Th1 cytokines were notably high, while Th2 cyto-
kines increased moderately. We observed significant
increase in the cytokine levels compared to the pre-bleed
level for any of the group. The level of cytokine was signif-
icantly higher in pCMV-E, pMS-E, pCMV-E/MbrAg
immunized mice in comparison to the groups inoculated
with pNIX-E and PBS. Hence the immune response was
skewed towards Th1 type and only moderate towards Th2
(Figure 6).
Lymphocyte proliferation assay
The ability of splenocytes to proliferate when stimulated
with the JEV Ag was analyzed through lymphocyte pro-
liferation assay. We observed a significant increase in
proliferation for pCMV-E, pMS-E, pCMV-E/MbrAg
immunized mice in comparison to the pNIX-E and PBS
inoculated groups (Figure 7). The response in prolifera-
tion increased on increasing the concentration of Ag
upto 20 μg. Spleen from two mice per group was used
for the assay.
Discussion
Immune system has devised modalities to overcome non-
specific, autoreactive immune response while optimally
maintaining the balance. Thus, immune response through
antigen presentation by non-hematopoitic cells would
actually be downregulated, while immune response gener-
ated through professional APC would be long term and
balanced. Failure to have second signalling, which lack in
non professional APC may lead to reduced immune
response or even anergy [51]. The promoter of CMV is
commonly used in mammalian expression system due to
its strong activity in large varieties of cells [52]. The
Table 1 Protection of mice challenged with lethal dose of Japanese encephalitis virus (strain 733913)
Plasmid Constructs Number of mice challenged Number of mice surviving Protection (%)
pCMV-E 8 7 87.5
pMS-E 8 6 75
pCMV-E/MbrAg 8 7 87.5
pNIX-E 8 0 0
PBS 8 0 0
0
0.2
0.4
0.6
0.8
1
1.2
1.4
pCMV-E pMS-E pCMV-E/MbrAg pNIX-E PBS
O
D
 
(
4
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n
m
)
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2nd Dose
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Figure 4 ELISA. Antibody response of BALB/c mice immunized with plasmid DNA of different constructs by intramuscular injection. First booster
dose was given after 21 days of first immunization and second booster after 36 days. Serum samples were collected on the given days and
stored at -70. Each column indicates the mean response ± SEM.
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in gene therapy constitutive expression is favoured [53].
On the contrary, to enhance the immune response of
DNA vaccine, gene expression was restricted only to pro-
fessional APC [54] and sometimes limited as a safety con-
cern [55]. DC is considered to be the most potent and
remained as highly preferred target cell. Although in a
study, targeting DC alone was reported insufficient [35].
After ex vivo evaluation of promoters active in macro-
phages [38], we have selected the highest expressing
constructs (macrosialin) and extended our study for in
vivo analysis of macrosialin along with CMV promoter
for comparison. JEV E protein expressed under these
promoters was used for evaluation of concept in terms
of antigen specific immune response. Induction of virus
neutralizing antibodies, protection from lethal challenge
and cytokine profile of immune splenocytes was studied
and compared. E protein of JEV is considered to be a
vital protein to target, because antibody against E pro-
tein has shown to neutralize JEV infectivity and also it is
functionally important [12,56].
All the plasmid constructs were tested and confirmed
to drive the expression of E gene of JEV before in vivo
inoculation. In transfection experiment, Western blot
and IFA analysis showed the constructs under study
expressed E gene with high efficiency in RAW 264.7
cells. This indicated that the plasmid could be used
further for subsequent in vivo experiments. Though we
have shown the expression of E protein in RAW264.7
cells as a qualitative test, still the noticeably higher
expression is seen with pCMV-E construct. We had
shown similar results quantitatively in our earlier study
using GFP reporter system [38].
To explore the applicability of these constructs as vac-
cine, groups of mice were vaccinated intramuscularly
with recombinant plasmids. In addition, to evaluate
prime boost models, administration of plasmid followed
by MbrAg as a booster was used. All constructs, pCMV-
E, pMS-E and pCMV-E/MbrAg (test groups) success-
fully led to the production of anti-E Ab. As measured
by ELISA, the Ab produced in pCMV-E and pMS-E
were nearly similar after the third dose, but increased
significantly in pCMV-E/MbrAg groups. To measure the
neutralizing abilities of these Ab, virus neutralization
test was carried out. pCMV-E/MbrAg group showed the
highest neutralizing Ab titre in all sera, whereas pCMV-
E and pMS-E showed similar titre after the second dose,
after the third dose the neutralizing Ab titre increased
significantly in pCMV-E groups. The increase in Ab
titre after subsequent dose shown by ELISA and neutra-
lizing test was similar in comparison shown by other
group (21).
For the evaluation of cellular response, lymphocyte
proliferation assay was carried out. Significant prolifera-
tive response was observed in the splenocytes of vacci-
nated mice when compared with either pNIX-E or PBS
inoculated mice. Similar proliferation indices were seen
in the group of pCMV-E and pMS-E, whereas pCMV-E/
MbrAg showed the highest response.
Cytokine has a major role to play in immune response
against viruses, through direct antiviral activity as well
as directing an array of immune responses to control
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Figure 5 Virus neutralization assay. Neutralization assay of sera from mice immunized with different constructs. The highest dilution of mice
sera that resulted into more than 50% CPE was considered. As a positive control JEV immune peritoneal fluid was used whereas peritoneal fluid
from the non immunized mice was used as a negative control.
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immunization governed by different promoters through
cytokine secretion profile of spleen cells. The result indi-
cated that the magnitude of cytokine production was
higher in pCMV-E in comparison to pMS-E at all times.
The cytokine level for pCMV-E/MbrAg group increased
dramatically after the second dose since it was boosted
by MbrAg which acted as a better immunogen. This
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Figure 6 Production of cytokines upon immunization of different constructs. CBA was performed with the supernatant for Th1 and Th2
cytokines. The graph represents the concentration of cytokines TNF, IFN-g, IL-2, IL-4 and IL-5. The data presented here are the means ± SEM of
cytokine profile after (A) Second dose, (B) third dose and (C) the ratio of IFN-g and IL-4 to show the skewness of immune response.
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demonstrated that DNA priming followed by protein
boosting results in greater humoral response and mixed
Th1/Th2 response with higher IFN-g,I L - 2a n dI L - 4
cytokines [58,59]. After the third dose increase in Th1
cytokine might have downregulated the Th2 cytokines.
To evaluate the ratio of Th1 and Th2 responses, we
observed the ratio of IFN-g/IL-4, interestingly we
observed macrosialin promoter highly skewed the
response towards Th1 cytokine in comparison to CMV
promoter. Our result for dominant Th1 response after i.
m. inoculation of plasmid is in agreement with the ear-
lier observation [21], moreover it also supports the pre-
viously observed Th1 biased response with APC
targeted Ag delivery [54,60,61].
To assess the efficacy of vaccine in terms of protec-
tion, mice were challenged with lethal dose of JEV. We
observed 87.5% protection in pCMV-E group and also
for pCMV-E/MbrAg group, whereas it was 75% in pMS-
E group. For protection to the host against JEV, neutra-
lizing Ab plays a significant role [20]. For viral infections
the importance of IFN-g has been amply demonstrated
[57]. Comparatively lower level of protection in pMS-E
could be attributed to lower neutralizing Ab titre and
lower IFN-g levels (after second dose) and its non signif-
icant rise after the third dose. TNF is a proinflamatory
cytokine considered efficient in stimulating DC matura-
tion, migration and induction of proliferative and cytoly-
tic activity of T cells and NK cells [62], for pMS-E lower
TNF level was observed in comparison to pCMV-E or
pCMV-E/MbrAg. With the acceptable difference in
overall immune response in the constructs, it is consid-
ered as evidence of protection if the neutralizing titres
are ≥ 1:10 [63].
In conclusion, CMV and Macrophage active promoter
constructs resulted in successful expression of the E
protein after intramuscular (i.m.) immunization. The
expression level of pMS-E was lower than those
obtained with the use of pCMV-E constructs but suffi-
cient to induce protection in mouse model.
Conclusions
In summary, we have demonstrated herein the ex vivo
expression of E protein directed by CMV and Macro-
phage active promoter. When compared its activity in
terms of immunity in mice model, response of pMS-E
was lower than those obtained with the use of pCMV-E
constructs but sufficient to induce protection in mouse
model. With further study the use of macrosialin pro-
moter could be an interesting alternative to the use of
ubiquitous promoter, especially for the treatment of
pathogen requiring dominant cellular immune response
such as viral or anti-cancer vaccine.
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